Inhibikase Therapeutics’ journey is a gripping biotech saga that began with a bold scientific challenge: could a targeted cancer drug’s blueprint be reimagined to alter the course of Parkinson’s disease? Founded by chemist Milton Werner, the company sought to overcome the long-fraught quest for disease-modifying neurodegeneration treatments by engineering brain-penetrant kinase inhibitors inspired by Gleevec’s success story. Despite promising preclinical work and a clinical hold cleared with resilience, their lead Parkinson’s candidate risvodetinib stalled in Phase 2 on efficacy, prompting a dramatic pivot toward pulmonary arterial hypertension (PAH) with a prodrug of imatinib designed to improve tolerability. Backed by robust financing and new leadership, Inhibikase now aims to unlock unmet needs in PAH while the founder spins out a separate venture to keep the Parkinson’s hope alive. This compelling tale reveals the raw realities of drug development, where scientific conviction meets harsh clinical data and strategic agility becomes paramount.

Transcript - https://empor.top/us/IKT

• I. Introduction & Episode Roadmap
• II. The Scientific Genesis: From Gleevec to Neurodegeneration
• III. The Founder's Journey: Milton Werner & The Birth of Inhibikase
• IV. The RAMP Platform & The Drug Candidates
• V. Key Inflection Points: The Clinical Journey (2019-2024)
• VI. The Dramatic 2024-2025 Pivot
• VII. The PAH Opportunity: New Frontiers
• VIII. Playbook: Business & Investing Lessons
• IX. Porter's 5 Forces & Hamilton's 7 Powers Analysis
• X. Bear Case vs. Bull Case
• Key Metrics to Monitor